ATIC missense variant affects response to methotrexate treatment in rheumatoid arthritis patients. (December 2016)

• Record Type: Journal Article
• Authors: Kurzawski, Mateusz; Malinowski, Damian; Szarmach, Natalia; Nowak, Anna; Goryniak, Aleksandra; Pawlik, Andrzej; Droździk, Marek
• Is Part Of: Pharmacogenomics. Volume 17:Number 18(2016)
• Page Start: 1971
• Page End: 1978
• Publication Date: 2016-12
• Subjects: folate pathway -- methotrexate -- rheumatoid arthritis; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs-2016-0125
• Languages: English
• ISSNs: 1462-2416

Abstract

Aim: The study was aimed at investigation of several gene variants of folate pathway enzymes for their potential association with methotrexate (MTX) treatment response in patients with rheumatoid arthritis.Patients & methods: Four hundred and twenty two Caucasian patients were classified as good or poor responders, and subsequently genotyped for common SNPs in DHFR, FPGS and ATIC genes.Results: No significant differences were observed in case of DHFR and FGPS SNPs. As for ATIC rs2372536 (Thr116Ser), GG minor genotype was significantly associated with good response to MTX (OR: 2.40; 95% CI: 1.30–4.42; p = 0.005), which was confirmed by multivariate analysis.Conclusion : The results of the study suggest that ATIC missense rs2372536 SNP may influence response to MTX therapy in rheumatoid arthritis patients.